Technologies
Philogen´s research and development activities for the identification of novel targeting agents rely on proprietary technology platforms such as antibody libraries and DNA-encoded chemical libraries. Both platforms have proven to deliver best-in-class ligands with high affinity and specificity and with powerful in vivo targeting properties.